Tagged with regulation

Pharma Providing universal health coverage to the nation’s roughly 10 million citizens, Hungary’s National Health Insurance Fund (OEP) has one of the most comprehensive and complex structures in Europe. The organization’s Head of Pricing Support, Dr. Judit Bidló discusses the current mechanisms governing pharmaceutical reimbursements in Hungary, while also identifying the…

Pharma Veronika Ferencz, Sales and Marketing Director for Exeltis Hungary, discusses the evolving and expanding footprint of the company in Hungary, the challenges strict regulations on food supplements are causing, as well as the need for better recognition of women’s health as a therapeutic area. She also reflects on her own…

Pharma The executive director of the Česká asociace farmaceutických firem, the Czech Republic’s generic pharmaceutical association, elaborates on the code of ethics recently implemented and followed by all its members, which exceed the standards set in current legislation. Furthermore, he explains the implications for the industry of the ongoing EU-level discussions…

Pharma The general manager of IMS Health, Zsolt Szepesházi, explains how the current limitations of Hungary’s healthcare system have shifted the way that pharmaceutical companies approach the market, placing a much greater emphasis on value demonstration and patient-level data. You have been General Manager at IMS Health for 8 years. During…

Pharma Genfit’s Jean-François Mouney speaks about responding to high unmet medical needs in inflammatory and metabolic related diseases. With the increase in obesity related diseases, Mouney discusses their lead pipeline product: Elafibranor, the new orphan blockbuster drug aimed at curing NASH; nonalcoholic steatohepatitis and other related diseases.   As an entrepreneur…

Pharma Novo Nordisk Hungary GM Zsolt Jozsa highlights the growing prevalence of diabetes in Hungary, the gap in treatment options that the company is striving to close with Tresiba and Xultophy, and the limitations of Hungary’s regulatory framework. Zsolt, you took over the helm of Novo Nordisk Hungary in 2012, after…

Pharma Janssen Czech Republic’s MD reviews his longstanding career within the company and highlights how founder Dr. Paul Janssen’s legacy still influences operations today. He also compares the Czech regulatory environment with those of its regional neighbors and finds that there is little ground for fair comparison. You have been with…

Pharma Concerted efforts are, at last, being made to redraw the rulebook and tidy up a local regulatory landscape long renowned for its torpor, dysfunction and ineffectuality. The Egyptian pharmaceutical market is currently regulated by the Ministry of Health itself, with all issues related to pharmaceuticals falling under the responsibility of…

Pharma Luigi Boggio, President of Assobiomedica, the association representing the medtech industry, and MD of B. Braun Italy, calls on the Italian government to implement a national system that measures the impact of medtech innovations. What are the exact activities of Assobiomedica and what are your main priorities as President? The…

Pharma Dr. Osvaldo Ponchiroli, CEO of OP Pharma, discusses the expertise his company can offer to help navigate Italy’s regulatory environment, the outlook for medium-sized generics companies in Italy and OP’s plans for international expansion. Dr. Ponchiroli, you founded OP pharma in 1996 as a data management and generics company mainly…

Pharma As CEO of the newly formed government agency Business France, Muriel Pénicaud is passionate about championing French innovation and creativity, particularly in life sciences. She tells us about her organization’s key objectives, ongoing efforts to change perceptions about France’s business environment, and her ‘bilingualism’ in the worlds of business and…

Pharma Alexander Zehnder discusses Sanofi’s sizable contribution to the Italian economy, manufacturing in Italy, and the country’s labyrinthine drug approval processes. What have been your main areas of focus and priorities since your appointment as head of Sanofi’s Italy and Malta operations in October 2014? Sanofi is in the midst of a transition from…